Medical Device Registration Services In Singapore

What Singapore medical device registration actually covers

Medical device registration in Singapore is a product-filing process with the Health Sciences Authority (HSA). For Class B, C and D devices, registration is generally required before the device can be supplied in Singapore. Class A devices are exempt from product registration, but HSA requires a Class A product notification in SHARE for Class A devices that are manufactured or imported. Dealer licensing is a separate control: a company that manufactures, imports or wholesales medical devices may need the corresponding dealer's licence for the activity it performs.

This page focuses on filing execution: who submits, how the application route is selected, what goes into the dossier, how the HSA review is handled and what has to be maintained after approval. For a broader product-compliance route map, see medical device compliance and certification in Singapore. For an IVD-specific filing, see Singapore HSA registration for IVD medical devices.

Who files the application and who remains responsible

The product owner authorises the registrant to prepare and submit the registration application to HSA. HSA's current submission guide requires a Letter of Authorisation from the product owner and treats the applicant/registrant as the party that submits the dossier and responds through SHARE. The registrant is therefore not just a document courier: the registration sits under that registrant and post-registration duties attach to the registration holder.

Do not confuse product registration with dealer licensing. A registrant relationship does not by itself replace the importer's, wholesaler's or manufacturer's licence that may be needed for actual dealing activities in Singapore. Before filing, confirm which Singapore entity will hold the registration and which entity or entities will import, wholesale or manufacture the device.

Select the filing route before building the final dossier

The evaluation route is not a free choice. HSA links it to the device's Singapore risk class, qualifying approvals from recognised overseas reference regulatory agencies, safe marketing history and the route-specific criteria. A device without a qualifying prior approval from an HSA reference regulatory agency goes through the full evaluation route. Some Class B, C and D applications with qualifying reference approvals may use abridged, expedited or immediate routes, subject to the detailed HSA eligibility rules.

Reference approval is not a shortcut if the Singapore device differs materially from the approved version. HSA expects disclosure of differences in design, commercial name, specifications, intended use/indications, labelling, packaging or IFU where relevant. The safe filing decision is made against the exact Singapore configuration, not only the brand name.

Build the dossier around HSA's current submission structure

For general medical devices, HSA accepts dossiers prepared using the ASEAN Common Submission Dossier Template (CSDT) or the applicable IMDRF non-IVD Table of Contents structure, with supporting documents uploaded to the corresponding folders in SHARE. The current October 2026 e-submission guide stresses correct folder placement and meaningful file names. IVD submissions have a separate HSA dossier guide and should not be forced into the general-device structure.

Core filing set

• Letter of Authorisation from the product owner to the registrant using the current HSA template.
• Complete list of device configurations covered by the submission.
• Proof of qualifying reference-agency approvals where a reliance route is used.
• Route-specific declarations, including labelling differences, marketing history and safety information where applicable.
• Executive summary and device description, including intended use, indications, risk class and relevant software/connectivity details.
• Essential Principles checklist, Declaration of Conformity and relevant standards information.
• Design verification and validation evidence appropriate to the device: for example biocompatibility, sterilisation, shelf life, electrical safety, EMC, software validation, cybersecurity, bench testing and biological-material evidence as applicable.
• Clinical evaluation evidence appropriate to the device and route.
• Labels and instructions for use for the Singapore supply configuration.
• Manufacturing-site and quality-system evidence required by the selected route and device type.

The dossier should be internally cross-checked before submission. Device names, models, software versions, manufacturing sites, intended use, reference approvals and labels should tell the same regulatory story across every document. A technically strong dossier can still attract avoidable Input Requests if its identifiers or scope are inconsistent.

Submission workflow in SHARE

1. Lock the regulatory identity of the product. Confirm that the product is a medical device, determine the Singapore class and define the exact models/configurations and intended use to be supplied.
2. Confirm the registrant and dealing structure. Put the product-owner authorisation in place and separately map any importer, wholesaler or manufacturer licence needed.
3. Select the HSA evaluation route. Test the exact device against reference approvals, marketing history and route exclusions before making the route declaration.
4. Freeze the dossier baseline. Use controlled versions of the configuration list, labels/IFU, approvals, declarations, verification/validation evidence and clinical evidence.
5. Submit through SHARE. Upload each dossier component to the correct supporting-document folder and pay the applicable fees.
6. Manage HSA Input Requests as controlled responses. Answer each query directly, identify any added file by name and ensure the response does not create new contradictions elsewhere in the dossier.
7. Close approval and SMDR listing. After a successful decision, verify the registered device details and scope before commercial supply.
8. Maintain the registration. Track annual retention, reportable safety events and field actions, and assess device or administrative changes before implementation where HSA notification is required.

HSA fees and target turnaround times to budget for

HSA's fee page was updated on 26 March 2026. The figures below are regulator fees and target turnaround times, not professional-service fees. HSA states that target review time excludes the time taken by the applicant to answer requests for clarification or additional information (the applicant's stop-clock).

Priority Review Scheme fees and target times apply to eligible Class B-D devices submitted under full evaluation, and HSA publishes separate figures for Class D devices with a registrable drug in a secondary role. Because route eligibility can change both dossier burden and regulator cost, confirm the route before giving a final filing budget.

Common rejection or delay triggers to eliminate before filing

• Wrong risk class or route. HSA warns that incorrect classification can require re-submission, and route eligibility must be supported by the exact approvals and history claimed.
• Mismatch with the reference approval. Differences in intended use, indications, model scope, labelling, packaging or IFU are not harmless if the selected route relies on that reference approval.
• Incomplete authorisation or configuration scope. The Letter of Authorisation and configuration list must cover the products actually submitted.
• Version drift. Software version, model names, accessories, manufacturing sites or document revisions differ between the application form, labels and evidence reports.
• Evidence without traceability. Test, risk, software, cybersecurity or clinical documents do not clearly map to the device version and claims being registered.
• Weak Input Request responses. A response answers only part of the question, adds unexplained new documents or creates a new inconsistency.
• Licensing assumptions. The product registration plan ignores the separate dealer's licence required for the actual import, wholesale or manufacturing activity.

What has to be maintained after registration

Approval is not the end of the filing lifecycle. Registered Class B-D devices remain on the Singapore Medical Device Register (SMDR) subject to annual retention. HSA also requires appropriate change notifications for changes to a registered device, and registrants/dealers have post-market responsibilities including complaint and distribution records, adverse-event reporting and field safety corrective action obligations where applicable.

A practical change-control rule is to assess regulatory impact before a planned technical, labelling, administrative or ownership change is implemented. Do not assume that a change accepted in another market can be rolled into Singapore without an HSA assessment.

What a registration filing service should deliver

A filing service should leave the manufacturer with a controlled submission, not just a completed web form. The minimum useful deliverables are: route and class confirmation, registrant/authorisation map, dossier gap list, indexed submission package, configuration and version reconciliation, SHARE filing support, Input Request response management, approval-scope check and a post-approval change/retention handover.

If the unresolved issue is strategic classification, product scope or whether an alternative route is available, that is an advisory problem before it is a filing problem. A filing team should identify that boundary rather than burying it inside document preparation.

Official HSA sources to verify before submission

• HSA medical-device guidance documents - includes current GN-15 product-registration guidance and October 2026 dossier guides.
• HSA registration overview - risk classes, evaluation routes and route eligibility overview.
• HSA fees and turnaround times.
• SHARE medical-device e-service.
• HSA dealer's licence application guidance.

FAQ about medical device registration in Singapore

Can a foreign manufacturer submit directly to HSA?

The product owner must have an authorised registrant/applicant able to submit through HSA's system. HSA's current dossier guide requires a Letter of Authorisation from the product owner to the registrant. The exact Singapore entity and account structure should be confirmed before the dossier is finalised.

Does a Class A medical device need HSA product registration?

Class A devices are exempt from product registration. HSA nevertheless requires product notification in SHARE for Class A devices that are manufactured or imported, and applicable dealer-licensing and post-market obligations still have to be considered.

Does CE marking or FDA clearance guarantee an abridged or immediate route?

No. A reference approval can support a reliance route only if it is a qualifying approval and the route's detailed conditions are met. The approved labelled use, device scope, safety history and other eligibility conditions must be checked against the Singapore submission.

How long does HSA registration take?

It depends on risk class and evaluation route. HSA's published target turnaround times range from immediate registration for eligible immediate routes to 310 working days for a standard Class D full evaluation. Applicant response time to HSA Input Requests is excluded from the target turnaround time.

What happens if the device changes after registration?

The registrant should assess the change against HSA's change-notification rules before implementation. Technical, review, administrative and certain safety-related changes may require notification or review, and the registered device information must remain accurate.